New Technology Captures Cannabis Strains in a Pill
The calm before the storm—founders of Harvest Direct Enterprises (HDE) setting up their booth. Zeyead Gharib (sitting) is the CEO, cofounder, and lead chemist at HDE and Ahmed Gharib (standing) is the cofounder and COO. Both have been instrumental in the invention of LACY and in bringing it to market.
Cannabis strains may have just been given the fast track to a pharmaceutical version (pill form) that captures the entire strain specific effects through the use of a device termed the lossless activation chamber Y (LACY). Zeyead Gharib, the cofounder, CEO, and lead chemist of Harvest Direct Enterprises, recently spoke to us about the LACY device, which won first place at the MJBizCon Battlefield, and the impact he’s expecting it will have in the cannabis industry, specifically the medicinal side.
Your company, Harvest Direct Enterprises, has developed a manufacturing method that lets you capture an entire cannabis strain in a pill using your lossless activation chamber Y (LACY) device. What led to the development of this method and how did you determine that there was a need for it in the cannabis industry?
We developed this method to solve a major problem in the industry: Traditional methods of activation and infusion degrade the cannabis plant profile. Prior to this development, nobody else in the history of cannabis or medicine had been able to make truly strain-specific, nonsmoked medicinal cannabis products. And why is that? The simple heating that is used in traditional activation and infusion methods degrades and purges the molecules that contribute to that strain’s specific effects (the entourage effect). Meaning that the specific medicinal properties of thousands of cannabis strains out there were lost during traditional activation and infusion. That loss was unacceptable to us. For patients, it was necessary that someone develop a way to capture and activate the full plant profile in a pill, inhaler, or topical-and our company, Harvest Direct Enterprises, was up to the challenge.
LACY is a decarboxylation device. Can you please tell us how that device is designed to work with cannabis?
The LACY device is able to activate and infuse cannabis with no loss or shift in the original plant profile we started with. This makes it the first system truly capable of making strain specific pills, inhalers, and topicals. Converting cannabis into a truly full spectrum, discreet, safe, consistent, and stigma-free form. This means that doctors will be OK with prescribing it, pharmacists will be OK dispensing it, and patients will be free to medicate discreetly and effectively.
How does the LACY method differ from other strain-specific extraction techniques?
LACY focuses on lossless activation, rather than just extraction. Lossless activation is what won us first place at the MjBizCon Innovation Battlefield in New Orleans, Louisiana. It’s what we can do that no one else can. Lossless activation is activating cannabinoids without degrading or purging the original plant profile. This means we can activate and infuse cannabis while maintaining the specific entourage effect of a specific strain-and that has never been done before.
What kind of impact do you anticipate LACY will have in the cannabis community?
LACY will absolutely and totally revolutionize the cannabis industry and the medical industry. In about 5 years-when it has full proliferation in the global cannabis market-targeted cannabis profiles will replace half or more of all of the current medications in use. That’s how far reaching and disruptive (in a good way) this technology will be. The biggest beneficiaries will be patients who will finally be able to consume the entire plant profile without smoking or vaping it, truly making cannabis a respected medicine while maintaining its holistic and natural properties (the entourage effect).
Can LACY capture specific strain information in any other forms aside from pills (for example, edibles, oils, topicals)?
Yes! LACY is a launching point; from there we can go into any product imaginable. We have already created the pill, and our next focus for research and development is the inhaler and topicals. We think the inhaler will be particularly revolutionary. Imagine a strain-specific inhaler that delivers the same effects as smoking within 30 seconds. We personally, cannot wait.
Inside the University of Maryland School of Pharmacy’s Graduate Program in Medical Cannabis
September 16th 2024Leah Sera, PharmD, MA, the co-program director for the University of Maryland School of Pharmacy’s Graduate Studies in Medical Cannabis program sat down with Cannabis Science and Technology to discuss higher education in medical cannabis.
Studying the Evolution of Cannabis Education: Insights from Stockton University’s Course Instructors
September 13th 2024A leader in cannabis education in New Jersey, Stockton University offers a wide variety of courses to prepare its students to not only succeed in an ever-growing industry, but to also understand its complex history and shape its evolving future. Started six years ago, its Cannabis Studies Program continues its commitment to providing innovative and practical instruction to its students. Two influential figures in this space are Robert Mejia, Teaching Specialist in the Cannabis Studies Program, and Angela Speakman, Instructor in the Cannabis Studies Program. Here, they highlight the program’s practical approach to cannabis education, celebrate the success stories of graduates, discuss the National Cannabis Curriculum Convening, and address challenges in cannabis education and its role in the future.
Medical Cannabis Campaigning with Americans for Safe Access
September 4th 2024As discussions about the federal scheduling of cannabis continue, efforts by medical cannabis advocates are intensifying. One such advocate is Americans for Safe Access (ASA), a nonprofit organization founded by patients for patients. Since 2002, ASA has been championing the rights of medical cannabis patients and has recently launched new campaigns and strategies to refocus attention on patient needs. In this interview, Steph Sherer, founder and president of ASA, reflects on past successes in medical cannabis advocacy, shares her perspective on recent cannabis and hemp policymaking, and outlines the next steps for advancing a unified medical cannabis message on Capitol Hill—a message that could bring about the changes patients have long awaited.
Insights on Cannabis Testing Challenges and Industry Standards: An Interview with Douglas Duncan
August 9th 2024In light of recent headlines concerning cannabis laboratories throughout the country, Cannabis Science and Technology reached out to Douglas Duncan, Laboratory Director of Kairos Labs in Detroit, MI and member of our Editorial Advisory Board for more information. In this interview, Duncan shares his perspectives on lab shopping, major challenges in the industry today, and innovations in cannabis testing laboratories for the future. He also shares insights into consumer practices and the potential effects of a federal rescheduling of cannabis.
Patients on the Front Line: Nikki Lawley’s Insights on Medical Cannabis Today
June 25th 2024In the ongoing dialogue surrounding cannabis, the testimonials of medical cannabis patients stand as crucial reminders of its impacts and benefits in the industry. For a deep dive into this topic, Cannabis Science and Technology sat down with Nikki Lawley, founder of Nikki and the Plant, LLC, for her take on the challenges patients face today in the midst of discussions of industry developments such as the rescheduling of cannabis. A traumatic brain injury survivor, Lawley now actively supports medical cannabis access and engages diverse audiences through her journey as a pediatric nurse-turned-patient-and-advocate. Here, she explains the importance of educating people about cannabis, the need for patient perspective in cannabis policy decisions, and the benefits of empathetic approaches to medical cannabis use.
Foundations for the Future: The University of Rhode Island’s Cannabis Education Program
March 5th 2024The continued expansion of the cannabis industry, particularly in the new recreational market in Rhode Island, is simultaneously increasing the opportunities for professions as well. One advantage here is education; formal training from experts provides an edge for those looking to lead and innovate in their field. In response to this need, the University of Rhode Island (URI) offers an Undergraduate Certificate in Cannabis Studies, a minor in cannabis studies, an upcoming Graduate Certificate in Cannabis Sciences, and more in order to evolve the way students learn and are prepared for the wide-ranging opportunities in the cannabis industry. In this interview, Program Director Stephanie Forschner-Dancause, PhD, shares insights into the curriculum of URI’s cannabis courses as they prepare students to ensure the industry's future is credible and grounded in evidence-based practices.
